AP Biosciences, Inc.

AP Biosciences is developing innovative antibody-related biotherapeutics targeting infectious, respiratory diseases, hematology and oncology. AP Biosciences, operates as a subsidiary of AbProtix, Inc. and partners with OBI Pharma Inc., (Taiwan).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.apbioinc.com
Founded2013
Disease Focus
Development StageTechnology
STOCK CODENon Listed
Address
17F , No.3 , Park St., Nangang Dist 115
Taipei city
China
Email
Contact Number
+886-2-26558010

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

AP Biosciences has developed integrated technolgy platform for functional antibody discovery and Omni-Mab Library – Human Antibody Phage Display Library for therapeutic antibodies discovery. AP Biosciences is developing large number of Mono & Bi-specific high-affinity, functional checkpoint antibodies isolated from Omni-Mab Library.

In 2016, OBI Pharma Inc., acquired 70% stake in AP Biosciences through issue of OBI Pharma shares to AbProtix, Inc. Further Financial details remains undisclosed.